Global Head, Janssen Diagnostics
Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.
In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.
Luc Truyen, MD, PhD.,
Global Head of Development & External Affairs, Neuroscience Therapeutic Area – Janssen R&D, LLC
Luc was trained as a neurologist in Belgium and the Netherlands with in addition a PhD in Medical Sciences from the University of Antwerp. After a career in academia with special interest in multiple sclerosis, stroke and neuro-degenerative disease he joined Janssen Research Foundation (JNJ) in 1998. He was part of the team that developed Reminyl/Razadyne™ for the symptomatic treatment of AD in early 2000’s. After that he has had roles of increasing responsibilities and scope within JNJ including Head of Global Clinical Development Operations for Pharma, Head of R&D and CMO for Janssen Alzheimer Immunotherapy etc. Luc was named VP Neuroscience External Affairs and Chair, Johnson & Johnson, Global Fight against Alzheimer’s Disease in April 2014. This to coordinate all efforts for J&J in the external environment related to AD (IMI, GAP, G7, etc). He is EFPIA co-lead for IMI-EPAD and the IMI 2 Neurodegeneration Strategic Governing Group, serves on the oversight committee of the Dementia Platform UK, is a member of the Scientific Advisory Board of the Dementia Discovery Fund and leads the industry advisory committee of the Global Alzheimer Platform. Recently Global Mental Health was added to the Ext affairs workportfolio. In January 2017 Luc was named Global Head of Development Neuroscience Janssen R&D LLC responsible for early and late development activities across neurodegeneration, mood disorders and schizophrenia.
J.D. Alvarez, M.D., Ph.D.
Vice President, Oncology Diagnostics, for the Janssen Pharmaceutical Companies of Johnson & Johnson
J.D. Alvarez, M.D., Ph.D. is Vice President, Oncology Diagnostics, for the Janssen Pharmaceutical Companies of Johnson & Johnson. In this position, he is responsible for developing and delivering diagnostic solutions that enable registration of compounds in the Oncology pipeline.
J.D. joined Janssen in 2009 as an Associate Director of Oncology Biomarkers and was responsible for establishing a molecular pathology laboratory to support oncology biomarker investigations and strategies. He has held positions of increasing responsibility within Biomarkers, Translational Research and Clinical Research. He also represents Janssen on working groups within the Society for Immunotherapy of Cancer, the Association of Molecular Pathology and the Medical Device Innovation Consortium.
Prior to joining Janssen, J.D. served as a research associate at the University of Pennsylvania conducting independent National Institutes of Health grant-funded research on the function of circadian rhythms in disease physiology. He also held positions in both discovery research and oncology translational medicine at Nippon Roche K.K. and at Wyeth Research.
J.D. received his medical degree and his doctorate in Molecular Cell Biology from the Washington University School of Medicine in St. Louis. He completed his residency and fellowship training through the University of Pennsylvania School of Medicine Department of Pathology and Laboratory Medicine. He is board certified in Anatomic Pathology and Molecular Genetic Pathology.
Mariano Alvarez, PhD
Chief Scientific Officer, DarwinHealth™
Dr. Alvarez obtained his Ph.D. in Chemistry and Molecular Biology from the University of Buenos Aires, Argentina, where his work and discovery programs focused on the interactions between tumor cells and the host immune system. Following his formal education, Dr. Alvarez was appointed Senior Scientist at a biotech company where he employed gene expression profile analysis to characterize molecular changes in the brain that were triggered by tumor growth at distal sites.
After postdoctoral training in the Califano Lab at Columbia University, Dr. Alvarez was appointed Research Scientist in the Department of Systems Biology at Columbia University.
Over the past nine years, in conjunction with Professor Califano, Dr. Alvarez developed the IP and core algorithms, including VIPER, that are currently deployed by DarwinHealth™ and that underpin the company’s foundational, oncotecture-driven technology platform. The platform has been successfully deployed for drug discovery, biomarker elucidation, and proteomic profiling across multiple disease states, with a focus on cancer.
This proprietary technology, the details of which have been published in the world’s leading scientific and medical journals, includes methods for the reverse engineering of regulatory networks, assessment of protein dysregulation, and computation-based inference of cell state checkpoints. His work related to the elucidation of targetable tumor checkpoints in cancer, identification of regulatory nodes implicated in neurodegeneration and behavioral disorders, and characterization of drug mechanism of action and synergy has been reported in more than 25 manuscripts published in top-tier scientific journals.
Ashish Atreja, MD, MPH
Asst. Professor & Chief Innovation Officer, Icahn School of Medicine at Mount Sinai
Dr. Atreja has received formal training in public health and is board certified in gastroenterology, clinical informatics and internal medicine. Over the last fifteenyears, he has led many public health and informatics initiatives at Cleveland Clinic and Mount Sinai Medical Center, NYthat includes developing online education modules, leading EHR implementation, performing analytics on healthcare data and developing enterprise-wide mobile apps. As Chief Innovation and Engagement Officer, Medicine, he leadsthe Sinai AppLab (http://www.applab.nyc) that is one of the first collaborative hub within academic medical center to build and test disruptive mhealth technologies. Dr. Atreja leads scientific registries for American Gastroenterology Association and serves in Innovation Advisory Board for American College of Cardiology. As an intrapreneur, Dr. Atreja has won innovation awards at Cleveland Clinic and Mount Sinai, successfully licensed technologies from academic centers and advises startups, accelerators and Fortune 500 companies in digital medicine. Recently, Dr. Atreja established Network of Digital Medicine (www.nodehealth.org) to connect innovation centers worldwide and share best practices for digital medicine innovation and implementationbetween industry, payers and health systems. Dr. Atreja serves as Scientific Co-founder for Mount Sinai Spinoff, Rx.Healththat brings first enterprise-wide app curation, prescription and engagement platform to risk sharing hospitals and payersin an affordable and scalable manner. Dr.Atreja has published more than 60 papers, presented more than 200 abstractsand has been a keynote speaker globallyon topics related to digital medicineand health system transformation.
Dina Avery, DHSc, MA, MAEd,
Assistant Professor & Regulatory Affairs Specialist, University of Alabama at Birmingham
Dr. Dina Avery is an Assistant Professor and Regulatory Affairs Specialist for the UAB Biotechnology Regulatory Affairs Program. She received her Bachelors of Science from the University of Montevallo (Sociology/Family & Child Studies). Dr. Avery also holds a Master of Arts (Health Studies) from the University of Alabama and a Master of Education (Adult Education) from the University of Phoenix and is currently completing a Master of Arts (Applied Sociology) from the University of Alabama at Birmingham. Dr. Avery completed a Doctorate of Health Science with a concentration in Global Health from A. T. Still University, School of Health Science.
Dr. Avery has professional experience with clinical research, health disparities research, community based participatory research, regulatory/compliance and program management in the areas of cardiovascular surgery, ophthalmology, neurology, preventive medicine and oncology. She has worked with underserved populations across Alabama’s Black Belt and the Mid-South region. While at the Glenn Family Breast Center at Winship Cancer Institute of Emory University, she was in charge of the day-to-day management of the breast tissue banking operations for three hospitals and was instrumental in working with a team to develop a new bio-banking infrastructure by enhancing the processes and web-based applications (LIMS & Subject Registry). In less than 1 year, she successfully strategized a plan that significantly increased the collection rate of blood and tissue samples from breast cancer patients for the biorepository. Dr. Avery was awarded funding in the areas of postpartum associated breast cancer disparities and triple-negative breast cancer disparities.
John M. Baldoni, PhD
Senior Vice President, In silico Drug Discovery, GSK Pharma R&D
John Baldoni is Senior Vice President, In silico Drug Discovery, in GSK Pharma R&D. This department employs in silico methods to identify patient needs, explore molecular interventions to address those needs and design and conduct clinical trials to test the medical hypothesis. Using these methodologies, the conventional empirical design make test cycle will be dramatically reduced. The intent is to discover medicines at higher velocity and with greater precision compared to current approaches. John is also Co-chair of ATOM, a public private partnership to advance the methodologies used to discover oncology medicines and put them in the public domain
Prior to this, John was Senior Vice President, Platform Technology and Science (PTS), in GSK. The work of PTS spans the entire drug discovery and development process, from preclinical activities leading to clinical candidate selection through commercial launch. This accountability covered the discovery and manufacture of small molecules, biopharmaceuticals, and cell and gene therapies.
John joined GSK in 1989 and has worked in the pharmaceutical industry for 38 years. His experience spans new chemical entity design, development and commercialization, and biopharmaceutical development. In progressing to his current role, John has held various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. He has led several key cross-functional strategic initiatives, such as advanced manufacturing technologies and discovery modernization
John has a BS in biochemistry (1974), and MS and PhD degrees in chemistry (1980) from Penn State University.
Annette Bakker, Ph.D.
President and Chief Scientific Officer, the Children’s Tumor Foundation
Annette Bakker, PhD, is the current President and Chief Scientific Officer of the Children’s Tumor Foundation, a non-profit that works to drive research, expand knowledge, and advance care for the neurofibromatosis (NF) community. She is directly responsible for managing the Foundation’s research, fundraising, outreach, and development operations, and has greatly expanded the Foundation’s research programs. She has served as the oncology head for a biotech company in Siena, Tuscany, where she built their oncology program from the ground up, and managed their neuro and oncology research initiatives throughout Europe and Asia. She has extensive experience acting as a liaison for pharmaceutical and biotech companies, and her research has been recognized internationally through peer-reviewed papers, awards, and patents. She was most recently the recipient of a 2017 RARE Champion of Hope Award for her notable efforts in science, presented by the rare disease patient advocacy organization, Global Genes. She is also a lecturer at the University of Alabama at Birmingham, and was a former oncology group leader at Janssen Pharmaceuticals in Belgium. She received her PhD in Cell Biology from the University of Antwerp, and completed postdoctoral fellowships at Yale University and La Salpetriere, Paris.
Michele M. Becci, MBA
Vice President, Industry Strategy at Medidata Solutions
Michele M. Becci, Vice President, Industry Strategy at Medidata Solutions, has nearly 30 years of experience in the life sciences industry. Since joining Medidata in 2013, Michele is responsible for helping to shape the industry strategy of the Medidata portfolio. Prior to her joining Medidata, Michele held various senior management positions in sales and marketing as part of Oracle’s Health Sciences Global Business Unit and was instrumental in the formation and growth of the health sciences portfolio of products at Oracle. Michele’s career began as a pharmacologist at Wyeth Ayerst Research. She holds a B.A. in Microbiology and an M.B.A. in International Business.
Christina Bender, PhD, MBA
Director, Global Diagnostic Pipeline Strategy – Novartis
Christina Bender is responsible for early commercial CDx strategy as part of Novartis Oncology’s global new products team. Following her postdoctoral studies in Molecular Biology (Cancer Mutagenesis) at London’s Imperial Cancer Research Fund in 1999, Christina began her professional career in the Biotechnology industry as a Genomics Sales Specialist for Molecular Devices Ltd, responsible for Region Europe. She returned to the US in 2001 to join Gyros US Inc. as a Key Account Manager, focusing on micro-fluidic technologies serving the Life Sciences and Diagnostics sectors. In 2005 she changed careers, joining the Pharma industry in a commercial marketing capacity at Novartis Pharmaceuticals. Christina has enjoyed a variety of marketing and business analysis roles at Novartis, including support of the Neuroscience franchise in the US General Medicines organization, and numerous product franchises across Global Oncology. She also lead Novartis’ BCR-ABL diagnostics commercialization efforts in support of the Tasigna-Glivec CML (chronic myelogenous leukemia) franchise. Christina received a B.S. in Biological Science from UCLA (university of California, Los Angeles), a Ph.D. in Biochemistry at USC (University of Southern California), and an MBA in Pharmaceutical Marketing from the Rutgers Business School.
Carol Berry, MBA
Senior Vice-President and Chief Business Officer, Caprion Biosciences Inc.
Carol has over 25 years of executive management experience in diagnostics, specialty laboratory testing in drug development and personalized medicine. Carol joined Caprion in January 2014 as the Chief Business Officer and Sr. Vice President responsible for the commercial strategy, business development, marketing, product development, and customer relations. Prior to joining Caprion, Ms. Berry served as the Senior Vice President and General Manager for Asuragen’s Genomic Services and CLIA Laboratory Division. While at Asuragen Ms. Berry was instrumental in the commercialization strategy of two diagnostic tests (Thyroid and Pancreatic). She led the companion diagnostic business development efforts securing 3 major CDx projects in two years. From 2002 to 2007 Carol was a member of the senior management team at Ciphergen Biosystems Inc., a proteomic equipment and pharmacoproteomic research company. At Ciphergen she was responsible for the diagnostic business development efforts and assessing the commercial potential of biomarker projects. The Ovarian Cancer study (OvaOne Test) was commercialized in 2007. Ms. Berry started her diagnostic career at Roche Biomedical Laboratories (now known as LabCorp) where she was one of the top fifty General Managers. Ms Berry has been an Advisory Board Member of the Women’s Business Leaders in Healthcare for 15 years and is an active participant in the Personalized Medicine Coalition. Today she is also involved with the First Tee Golf Organization which provides educational programs that build character, instill life-enhancing values and promote healthy choices through the game of golf.
Carol received her Bachelor of Science Degree from Texas A&M University where she was a four year Letterman on the Women’s Golf Team. She received her MBA Degree from University of Dallas in 2004.
Director – Diaceutics Inc.
Wayne serves as Marketing Director for Diaceutics Inc., a global diagnostic planning and commercialization service provider headquartered in Ireland with satellite offices in the US, Asia and South America. Diaceutics works with their pharmaceutical clients, and directly with laboratories to provide an end-to-end service to integrate diagnostic testing into the treatment pathway, with the goal of assuring earlier and better testing that enables patients to get the right drug at the right time. Diaceutics work is enabled by a robust flow of clinical diagnostic data from their 2900+ global laboratory partners.
Wayne’s background is pharmaceutical marketing and early commercial development with Bayer and BMS in Canada and the US. He has also held client consulting and business development roles with leading data and analytics organizations supporting pharma.
Jim Cassidy MD PhD
Corporate VP, Celgene
Jim Cassidy MD PhD is Corporate VP at Celgene. He heads up the translational development team covering both heme and solid cancers. Jim was a full Professor of Oncology for close on 20 years at Aberdeen University and at The Beatson Institute of Glasgow University before joining Pharma in 2011. Since then he has worked at Roche and BMS in roles of increasing seniority and responsibility within early clinical and translational development functions. He is best known for his clinical and academic work in the field of GI cancers – with over 250 peer reviewed publications and contributions to 5 books. He was the senior founding author of the Oxford University Handbook of Oncology which has been a Worldwide best seller for over a decade.
Gregory J. Downing, D.O., Ph.D.
Founder of Innovation Horizons, LLC
Dr. Downing the Founder of Innovation Horizons, LLC, a Washington, D.C.-based health care and innovation consulting group focused on the applications of data in care delivery transformation initiatives. He has over 26 years of executive leadership in the federal government across multiple federal agencies, including the Office of the Secretary including the Immediate Office of the Secretary and the National Institutes of Health, in the United States Department of Health and Human Services (HHS). He has serve in extensive policy setting roles including science and technology advisory capacities to multiple NIH Directors, National Cancer Institute Directors, and 4 HHS Secretaries. For four years under HHS Secretary Michael Leavitt, he led the Department’s Personalized Health Care Initiative which facilitated trans-agency collaborations on the enablement of personalized medicine through the coordination of research, regulatory practices, and policy, including implementation of the Genetic Information Non-discrimination Act of 2008. From 2009 though 2017, led the development and implementation of HHS’ health data transparency and open innovation initiatives, serving as the founding executive director for innovation at HHS, and led the development of the HHS Secretary’s innovation center, IDEALab.
In current practice, Dr. Downing assists organizations by designing programs, strengthening infrastructure, and enhancing leadership capabilities that are aimed collectively at raising their innovation capacity. He serves in consultancy roles to health systems, technology and clinical care service companies, national and international federal government health agencies, and civil society organizations to establish solutions for health care systems challenges through the use of health, health care, and other publicly available data sources. Since 2017, Dr. Downing has served as a senior scholar-in-residence at AcademyHealth, a non-profit organization focused on health systems research and evidence-based practice, where he is focused on developing strategies for adoption of data and technology to facilitate health care decisionmaking. Dr. Downing is adjunct professor of practice at Georgetown University where he leads the innovation in health care management track. His team’s specialty practices include leading innovative data applications and user-centered design approaches to care delivery settings that address multiple dimensions of health systems, provider practices, and patient health care experiences. His current research interests are in metrics and outcomes-based approaches to health care transformation, including specialty interests in behavioral entrepreneurship, and social impact innovation practices. He has extensive experience in the uses of health information technology platforms including those supporting predictive sciences, and is developing clinical use applications of machine learning approaches with academic and commercial interests to facilitate clinical evidence evaluation. He is the author of more than 80 peer-reviewed publications, and multiple books and monographs on biomedical and health care research practices.
Dr. Downing also maintains an active medical practice in newborn pediatrics and is certified by the American Board of Pediatrics. He earned his medical degree from Michigan State University, completed his pediatric residency at the University of Medicine and Dentistry of New Jersey, and was a neonatology fellow at the Children’s Mercy Hospital in Kansas City, MO. He holds an B.S. degree in pharmacy from Ferris State University and a Ph.D. in pharmacology from the University of Kansas.
Founder & Director, Latino Cancer Institute
Ysabel Duron launched the Latino Cancer Institute (LCI) in 2016, with a 35-thousand grant from the California Health Care Foundation. The Latino Cancer Institute connects Latino cancer serving agencies nationwide to share best practices and develop capacity; convenes events for stakeholders in the cancer landscape to provide opportunities to collaborate with cancer researchers focused on Latino cancer challenges; advocates at a national level to raise awareness of Latino cancer issues, promote policy, and attract major funding bodies.
Duron’s experience spans 17 years in the Latino cancer space with the development of two non-profit agencies. She drove development of programs to address gaps across the cancer continuum from community education and screening to psychosocial support groups. In 2010, Duron successfully piloted a lay community navigator program in the public health care system cancer center in San Jose, CA dedicated to providing support for the low income, Spanish speaking patient. Ten years ago she launched the biennial National Latino Cancer Summit under the auspices of UCSF bringing community together with researchers to network, learn from each other and find ways to collaborate. In 2016 the Summit spot lighted Precision Medicine concerned the cutting-edge science would exacerbate disparities.
Duron has earned a reputation as a key opinion leader about Latino cancer issues. A 43-year award winning TV journalist, Duron stepped away from a career in San Francisco in 2013 and dedicated herself fulltime to turning the spotlight on the Latino cancer burden. Duron serves on the Independent Review Board (IRB) for the All of Us Research Program at the National Institutes of Health (formerly President Obama’s Precision Medicine Initiative) and a Genomic Working Group Committee for the NHGRI. Duron has received numerous awards including the Purpose Prize from Encore.org; the Juliette Gordon Low Award from the Girl Scouts, and the Latino Spirit Award from the California Latino Caucus.
Jim Fackler, M.D.
Associate Professor, Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine
Dr. Fackler’s clinical work is pediatric critical care and anesthesiology at Hopkins. Before taking his current role at Hopkins in 1996, he was on the faculty of the Harvard Medical School where he assisted in the founding of the Children’s Hospital Informatics Program. He worked for the Cerner Corporation from 2002 to 2006 and was responsible for the development and deployment of their critical care solution suite. His academic interests are the harnessing of the data generated by, and about, critically ill children for use in identifying and reducing the clinician driven variability in the care of complex conditions (such as sepsis). He founded a startup, Rubicon Health, to make the variability in healthcare delivery patient-centric and not clinician-idiosyncratic.
President & CEO, LUNGevity Foundation
Andrea is President and CEO of LUNGevity Foundation. She became involved with lung cancer advocacy following her mother’s death from the disease in 2008. After receiving a diagnosis of stage IV lung cancer in 2006, Andrea’s mother underwent numerous treatments and clinical trials at several major academic institutions to no avail. Together with her father, Andrea was her mother’s primary caregiver during this time. Determined to drive more money into lung cancer research, Andrea left the successful software company that she helped launch, to found Protect Your Lungs, an organization focused 100% on funding early detection research. In 2010, Andrea merged Protect Your Lungs with LUNGevity, a Chicago based organization, to form the nation’s leading lung cancer focused non-profit.
Andrea’s strong business background combined with her connections to the worlds of research and advocacy have enabled her to build the preeminent patient advocacy organization in the lung cancer space. LUNGevity funds translational research into both early detection and more effective treatments of lung cancer as well as a highly coveted Career Development Awards program. LUNGevity also fills unmet needs for people diagnosed with lung cancer by providing education, support and survivorship programs. Recognizing the need to build awareness and understanding about lung cancer, LUNGevity has built the largest grassroots network of events and advocates across the country.
Ryan Fukushima, MBA
Chief Operating Officer, Tempus
Ryan Fukushima serves as Chief Operating Officer at Tempus and joined the company as the first employee. Prior to Tempus, Fukushima was an Entrepreneur-in-Residence and Vice President at Lightbank, focusing investments on enterprise software and launching businesses. Earlier he was at Hyde Park Venture Partners, where he concentrated on enterprise investments in the Midwest. Before landing in Chicago, Fukushima worked predominantly as an engineer, designing and implementing backend systems for Cisco and VMware. Fukushima has received a bachelor’s degree in Engineering from California Polytechnic University and holds an MBA from the Ross School of Business at University of Michigan, where he was a Zell Scholar.
Anita Krithivas Gandhi, Ph.D
Senior Director, Translational Development and Diagnostics Department, Celgene Corporation
Anita Krithivas Gandhi, Ph.D., is currently Senior Director, Translational Development and Diagnostics Department, Celgene Corporation, Summit, New Jersey. Dr. Gandhi studied at Tufts University for her undergraduate in Biological Sciences. She subsequently did research at the Dana Farber Cancer Institute in Boston and completed her Ph.D. in Molecular Pharmacology at the Johns Hopkins School of Medicine in Baltimore, Maryland. Her graduate work focused on the link between human herpes viral proteins and cancer.
Dr. Gandhi joined Celgene Corporation in 2002 for her post-doctoral research involving immunomodulatory agents and their mechanism of action in multiple myeloma and myelodysplastic syndromes. She was a key contributor to the current understanding of the Cereblon binding agents and modulators of E3 ubiquitin ligases and subsequent links to the pleiotropic activity of these agents on both tumor and immune cells in hematological malignancies. Dr. Gandhi served as the lead translational scientist for the CC-122 discovery and translational program bringing CC-122 from the pre-clinical stage through Phase 1b including development of a companion diagnostic. Dr. Gandhi’s translational research for CC-122 focused on the mechanism of action, differentiation from other cereblon binding agents, establishing a unique schedule in the clinic and identifying a gene expression biomarker for patient selection in lymphoma. Dr. Gandhi’s current role as Lymphoma Translational Disease Strategy Lead focuses on lymphoma disease biology to enable rational drug development and patient selection approaches for unmet need.
Dr. Gandhi is widely published and internationally recognized as a scientific leader in the field of targeted protein degradation and development of these agents in hematological malignancies.
Marc Grodman, MD
Co-Founder & CEO, Genosity
Marc Grodman M.D. Is the founder and CEO of Genosity LLC., a start up biotechnology company focused on unlocking the power of precision medicine by providing a technology platform and services to advance clinical genomics and facilitate drug discovery and collaborative research. Dr. Grodman has been a leader in driving innovation in new critical areas of diagnostic testing. As the founder of BioReference in 1981, he oversaw unprecedented organic growth while fostering a culture of innovation and entrepreneurial spirit that led to the evolution of a small regional clinical laboratory into one of the largest clinical laboratories in the US with annual sales approaching $1B and a world-renowned provider of genetic and genomics testing. BioReference was acquired by OPKO Health in June 2015.
Throughout his career, Dr. Grodman has driven innovation in new critical areas of diagnostic testing, bringing clinically relevant information to physicians, as well as formatting data to enhance patient care and scientific advances. Leading a team of premier scientists, Dr. Grodman has created innovative programs in the areas of cancer, genetics and women’s health.
In 2006, BioReference acquired GeneDx, a $5 million laboratory that only tested for rare and ultra-rare single gene disorders and turned it and other sequencing services at BioReference to almost $200M in revenue across multiple clinical areas. Over the next decade, under Dr. Grodman’s leadership, GeneDx became the first commercial laboratory to offer next generation sequencing (multiple gene testing for specific clinical problems) testing. GeneDx became the world leader in clinical exome testing, bringing answers to end the diagnostic odyssey primarily by analyzing over 20,000 genes at the same time.
Dr. Grodman played a vital role in laboratory industry as Chair, Vice Chair and Board Member of the American Clinical Laboratory Association, leading efforts to address issues such as the challenging reimbursement environment, FDA and CMS regulations, guidelines for testing, competitive bidding, PAMA, patient copay and associated changes with regard to passage and implementation of the Affordable Care Act. While CEO of Bio-Reference Laboratories Inc. he served on the Executive Committee of the Health Care Leadership Council and as Chairman of the Patient Safety and Quality Task Force.
Dr. Grodman has been on staff at Columbia University Vagelos College of Physicians and Surgeons since 1983, made teaching rounds for over 25 years, created and endowed new programs in alternative career tracks for medical students. He co-founded and serves on the steering committee of University-wide initiative Working Group on Global Health Security and Diplomacy. He is a trustee and fellow of the New York Academy of Medicine and on the Board of the Actors Fund of America as well as serving on the Columbia University Medical Center Board of Advisors.
Dr. Grodman obtained his BA from the University of Pennsylvania, his MD from Columbia University College of Physicians and Surgeons, attended Harvard University’s Kennedy School of Government, and was a Primary Care Clinical Fellow at Massachusetts General Hospital.
Sarah Hersey, MS, MBA, RAC
Head of Precision Medicine and Companion Diagnostics, Celgene Corporation
Sarah is currently the Head of Precision Medicine and Companion Diagnostics for Celgene Corporation. She has more than 20 years of industry experience in leading R&D organizations, CLIA laboratories, device manufacturing, assessment and implementation of technology strategies and development of in vitro diagnostics. Prior to joining Celgene, Sarah joined Novartis as a Global Program Diagnostics, Executive Director and prior to joining Celgene was the Global Head of Future Precision Medicine for Novartis, where the team submitted multiple pre-market applications including one for NGS. Sarah has also held multiple roles with increasing responsibility within Johnson and Johnson including Global Head of Operations, Assay Program Leader for Companion Diagnostics Center of Excellence, Director of Materials Process Development and Enabling Technologies. In addition, her prior experience also includes start-up and establishment of a pre-clinical GLP laboratory, technical support and quality assurance. Sarah has BS and MS degrees in Chemistry and Biology from Northern Illinois University, Regulatory Affairs Certification (RAC) and an MBA from California State University.
Jeffrey R. Idle, PhD
Endowed Professor and Director, Arthur G. Zupko’s Systems Pharmacology and Pharmacogenomics, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University
Academic biochemical pharmacologist and pharmacogeneticist. PhD St Mary’s Hospital Medical School (SMHMS) with Professor R. Tecwyn Williams, FRS. Co-discoverer in 1977 with Professor Robert L. Smith of the debrisoquine 4-hydroxylation polymorphism (CYP2D6). Wellcome Trust Senior Lecturer and Reader in Pharmacogenetics at SMHMS. Appointed at University of Newcastle in 1988 to first chair in pharmacogenetics. Head of Department of Pharmacological Sciences and Head of School of Clinical Medical Sciences at University of Newcastle. Appointed in 1995 Professor in Medicine and Molecular Biology at the Norwegian University of Science and Technology, subsequently Professor of Pharmacology, First Faculty of Medicine, Charles University Prague, then Visiting Professor at the University of Bern, Switzerland until 2016. Since 2002, contractor and consultant at the Laboratory of Metabolism (Chief, Frank J. Gonzalez, PhD), National Cancer Institute, NIH. Currently, Endowed Professor and Director, Arthur G. Zupko’s Systems Pharmacology and Pharmacogenomics, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn. Published over 300 articles and book chapters in drug metabolism, pharmacogenetics and metabolomics.
Jay S Kaufman, Ph.D.
Professor, Department of Epidemiology, Biostatistics and Occupational Health, McGill University
Jay S. Kaufman holds a PhD in epidemiologic science from University of Michigan (1995). He was previously a professor at UNC School of Public Health in Chapel Hill (1999-2008) and is currently Professor in the Department of Epidemiology, Biostatistics and Occupational Health at McGill University (2009-present). He also holds adjunct or visiting appointments at Schools of Public Health in the US, France and Chile. His work focuses on population and global health, racial/ethnic health disparities, heterogeneity of treatment effects, social epidemiology, and causal inference methods. He is an editor at the journal Epidemiology and an associate editor at the American Journal of Epidemiology. He is the author or co-author of more than 350 peer-reviewed publications in the biomedical and social sciences, and with J. Michael Oakes he is the co-editor of the textbook “Methods in Social Epidemiology” (2nd Edition, 2017).
Kevin Kalinsky, M.D., M.S
Assistant Professor of Medicine at the NewYork-Presbyterian Hospital/Columbia University Medical Center
Kevin Kalinsky, M.D., M.S. is an Assistant Professor of Medicine at the NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Kalinsky received his undergraduate B.A. from Emory University. He received his M.D. from the Medical University of South Carolina and completed his Internal Medicine internship and residency and Hematology/Oncology fellowship at Tufts Medical Center. In Boston, he also trained as a breast cancer clinical research fellow at Massachusetts General Hospital. In addition, he completed an advanced oncology fellowship in breast cancer at Memorial Sloan-Kettering Cancer Center. Since joining as a faculty member, Dr. Kalinsky completed a Master’s program in Biostatistics, Patient–Oriented Research at Columbia.
Dr. Kalinsky cares for patients diagnosed with breast cancer and teaches on the Breast Oncology service. He was recently awarded the Ewig Clinical Scholar Teaching Award at Columbia. Dr. Kalinsky’s research involves the development of early phase clinical trials to assess novel therapeutic agents in breast cancer based on tumor genomics. His work is funded by a number of sources, including the National Institute of Health and SWOG/Hope Foundation, and is a recipient of the 2017 NCI Cancer Clinical Investigator Team Leadership Award.
Peter Kapitein, PhD
As a Patient Advocate of Inspire2Live Peter connects patients, researchers and clinicians to further research, treatments and care; in the Netherlands as well as international. He organizes congresses, lobbies the matrix of public authorities, health care organizations, insurance companies and health research institutes. Peter also gives lectures and talks to help patients and society to fight cancer where possible and live with cancer with a good quality of life. He writes blogs, articles and books that contribute to these topics. Peter shows people their shining and radiant possibilities in every possible situation and lets them exploit their talents in favour of others. He’s creating Awareness and Hope where hope comes through vision.
Peter is the co-founder of Alpe d’HuZes, the foundation that is most famous for the annual cycling event on Mount Alpe d’Huez and that raised over 125 million euro for the fight against cancer. He works at the Central Bank of the Netherlands as a program manager and advisor for complex and politically difficult problems. His employer facilitates him in this job. Peter was honoured with a doctorate in October 2012 at the Free University in Amsterdam for connecting patients, researchers and clinicians all over the world to contribute to the quality of life of patients and their loved ones.
Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service, The William and Joy Ruane Chair in Thoracic Oncology, Lead Physician, Memorial Sloan Kettering–IBM Watson Collaboration
Mark G. Kris is an Attending Physician in the Thoracic Oncology Service at Memorial Hospital, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, N.Y. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology. Dr. Kris is a Professor of Medicine at the Weill Cornell Medical College. Since 2012, he has served as the Lead Physician for the Memorial Sloan Kettering – IBM Watson Collaboration.
Dr. Kris graduated from Fordham University. After receiving his medical degree from Weill Cornell Medical College, he served as Chief Medical Resident and Fellow in Medical Oncology at Memorial Sloan Kettering Cancer Center.
He is author or coauthor of over 300 original scientific publications. Dr. Kris served as a member of the guideline panels on non-small cell lung cancers and antiemetics for the National Comprehensive Cancer Center Network from 1995-2015. He serves as co-chair of the American Society of Clinical Oncology guideline panels for adjuvant chemotherapy and radiation for non-small cell lung cancers and Antiemetics for the American Society of Clinical Oncology. He is a Fellow of the American College of Physicians, The American College of Chest Physicians, and The American Society of Clinical Oncology. He received the first American Society of Clinical Oncology Humanitarian Award in 2011. Dr. Kris also received the Annie Blount Storrs Award from Calvary Hospital 2014.
Dr. Kris is a specialist in lung cancers and other tumors arising in the chest. He is particularly interested in developing ways to choose treatments for patients based on molecular characteristics of their tumor specimens. His research also includes the evaluation of new anticancer agents (particularly those targeting lung cancers), multimodality therapy (using surgery, radiation and drugs together to improve outcomes for individuals with thoracic cancers), and the training of the IBM Watson cognitive computer to assist physicians and patients in choosing the best treatments.
Eric B. Kmiec, Ph.D
Founder and Director of the Gene Editing Institute at the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System
Dr. Eric B. Kmiec is the Founder and Director of the Gene Editing Institute at the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System. His translational research focuses on gene editing, specifically using CRISPR, to catalyze genetic reengineering. Dr. Kmiec holds faculty appointments at the University of Delaware and the Wistar Institute. His laboratory has been continuously supported by the National Institute of Health grants with other funding from the National Science Foundation, the NIST-BIRD Foundation, and the American Cancer Society, among many others. Dr. Kmiec has been the primary thesis advisor for 18 PhD doctoral students as a full, tenured Professor at the University of Delaware and is the founder of two biotechnology companies. He serves on five editorial boards, has authored 160 peer-reviewed publications, as primary or senior author, and edited several books on gene therapy. Dr. Kmiec has 15 issued patents and has received service medals and awards, including the Genome Canada Lectureship, the Proudford Research Award and the PICC Life Science Innovator Award in 2018. Dr. Kmiec was named an Honorary Commander at Dover Air Force Base and an Eminent Scholar at Marshall University
Michael Kolodziej M.D.
Vice President and Chief Innovation Officer, ADVI Health
Michael Kolodziej M.D. is Vice President and Chief Innovation Officer, ADVI Health. Dr. Kolodziej attended college and medical school at Washington University in St. Louis where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at the University of Oklahoma School of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He joined Aetna in January, 2013 as National Medical Director, Oncology Solutions. While at Aetna, he directed Aetna’s oncology delivery reform pilots and was the architect of the Aetna Oncology Medical Home program. He was also active in Aetna’s pharmacy policy, condition analysis, and genetics subcommittees. Dr. Kolodziej joined Flatiron Health in July, 2016 as National Medical Director, Managed Care Strategy where he applied the core tech and data capabilities of Flatiron to facilitate practice transformation and success in alternative payment models. He joined ADVI in October, 2017. He is a Fellow of the American College of Physicians. He has published and spoken extensively on payment reform, personalized medicine, and practice care delivery transformation in oncology.
Andrew Kung, MD, PhD
Pediatric Oncologist, Chair, Department of Pediatrics, MSKCC
Dr. Andrew Kung, MD, PhD is a physician-scientist and Chair of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSKCC). His clinical expertise is in cancer genomics, precision medicine and stem cell transplantation. His research laboratory is focused on identifying the causes of pediatric cancers and developing new treatments to benefit children and adolescents with cancer.
Dr. Kung received his M.D. and Ph.D. degrees at Stanford University School of Medicine and completed post-graduate medical training as a pediatric oncologist at Boston Children’s Hospital and the Dana-Farber Cancer Institute. He served as a faculty member at Harvard Medical School and Columbia University Medical Center prior to joining MSKCC to lead one of the largest pediatric oncology programs in the world.
Working with his colleagues, Dr. Kung takes a translational approach to cancer research, integrating diverse disciplines with the ultimate goal of clinical translation. The research in his lab focuses on identifying new targets for anticancer drugs, the genomics of cancer, and the development of innovative therapies that target the molecular abnormalities fueling cancer growth. Studies from his lab have led to new clinical trials for leukemia, brain tumors and sarcomas.
Arturo Loaiza-Bonilla, MD MSEd FACP
Chief of Medical Oncology and Medical Director of Research at Cancer Treatment Centers of America – ERMC, and also Co-Founder and Chief Medical Officer at Massive Bio
Dr. Arturo Loaiza-Bonilla is the current Chief of Medical Oncology and Medical Director of Research at Cancer Treatment Centers of America – ERMC, and also Co-Founder and Chief Medical Officer at Massive Bio (www.massivebio.com). A precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institutes of Health, his major interest focuses in the field of innovative approaches to match oncology patients to phase 1-3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient’s overall status under an Artificial Intelligence-based and machine learning platform, which integrates to the electronic medical record. His company and virtual tumor board / clinical trial matching platforms have been recently featured in GenomeWeb and MedPage Today, including a first-in-the-world registry, SYNERGY-AI to match cancer patients based on Artificial Intelligence (https://clinicaltrials.gov/ct2/show/NCT03452774)
Dr. Loaiza-Bonilla is Principal and co-investigator on several Phase I/III clinical trials in several malignancies at Cancer Treatment Centers of America, with emphasis in new targeted therapies, novel molecules and immunotherapy, tailored to specific tumor type, its genomics and protein expression profiles. He is also a passionate advocate for improved access to medical care, precision oncology, medical education, organized medicine leadership and health policy, having been awarded the ‘Top 40 Under 40’ award by the Philadelphia Business Journal, AMA Foundation Leadership Award, Fellowship of the American College of Physicians, and holding a Master in Medical Education (M.S.Ed) degree from the University of Pennsylvania. He has held several leadership positions in state and medical societies, including his current tenure as executive board member of the Pennsylvania Society of Oncology and Hematology, and his role as President of the Board of Directors of the Global Alliance for Patient Access.
J Blake Long, MD, MBA
President, Long Health Care Consulting
Blake is focused on driving innovation in clinical science and health care delivery through both entrepreneurial ecosystem development and capital deployment based on experience in health care delivery, payment and investing. As President of Long Health Care Consulting, Blake provides clinical expertise, strategy analysis for both provider and payer markets, and capital acquisition support to early stage health care companies, as well as, innovation groups and investment firms.
Blake previously served as Chief Clinical Officer of Echo Health Ventures, the venture capital/private equity investment group of BlueCross BlueShield of NC and Cambia Health Solutions, providing clinical and strategy expertise to the evaluation of investment opportunities and working with portfolio companies on collaboration with providers and insurers. Prior to the formation of Echo in 2016, he served a similar role as Chief Clinical Officer of Mosaic Health Solutions.
Before joining Mosaic in 2015, Blake served as a practicing pediatric cardiologist at Savannah Children’s Heart Center and as a clinical professor at Mercer University School of Medicine. He also served as director of life sciences for Ariel Southeast Angel Partners, managing evaluation and implementation of investments in healthcare and life sciences. Previous roles have included chief medical officer and chairman of pediatrics in healthcare systems in Georgia.
Blake earned his BA and his MD from Duke University. He completed his residency in pediatrics at Walter Reed Army Medical Center, fellowship at Duke Medical Center, and served in Desert Shield/Storm. He received his MBA from Duke’s Fuqua School of Business in December of 2015.
Founder and CEO of Alva10
Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Diagnostics are the key to Precision Medicine, but they need to be valued in the healthcare market in order to be successful. For years, diagnostics have been stuck in a downward cycle of value, with poor reimbursement leading to lack of investment, and lack of investment leading to sub-optimal clinical validation, leading back to poor reimbursement. Alva10 is changing that, bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies using a proprietary algorithm to determine economic impact of diagnostics and create a new value based healthcare model.
Jennifer Manly, PhD
Associate Professor of Neuropsychology in Neurology at the Taub Institute for Research in Alzheimer’s Disease and the Aging Brain at Columbia University
Jennifer Manly, Ph.D. is an Associate Professor of Neuropsychology in Neurology at the Taub Institute for Research in Alzheimer’s Disease and the Aging Brain at Columbia University. Her research focuses on mechanisms of disparities in cognitive aging and Alzheimer’s disease. She received Early Career awards from the Society for Clinical Neuropsychology and from the National Academy of Neuropsychology, received the Tony Wong Diversity Award for Outstanding Mentorship, and is an APA Fellow. She served on the HHS Advisory Council on Alzheimer’s Research, Care and Services from 2011 – 2015 and is a current member of the Alzheimer’s Association Medical & Scientific Research Board.
Maurie Markman, MD
President of Medicine & Science at Cancer Treatment Centers of America.
Maurie Markman, MD is President of Medicine & Science at Cancer Treatment Centers of America.
For more than 30 years Dr. Markman has been engaged in clinical research in the area of gynecologic malignancies, with particular focus on new drug development and exploring novel management strategies in female pelvic cancers.
Dr. Markman has been the primary author or co-author on over 1,000 published peer-reviewed manuscripts, reviews, book chapters, editorials or abstracts, and has written, edited or co-edited 23 books on various topics in the management of malignant disease.
In 2011, Dr. Markman received the American Society of Clinical Oncology (ASCO) Statesman Award, which recognizes individual members who have shown extraordinary volunteer service, dedication and commitment to ASCO, their hospital community and the patients they serve for at least 20 years.
In May, 2018, Dr. Markman was named by OncLive® to an elite group of 21 inductees of the 2018 Giants of Cancer Care® recognition program. The program celebrates pioneers, innovators and leaders who have made remarkable achievements in oncology research and clinical practice. Dr. Markman was selected by his peers in recognition of his contributions in gynecologic cancers.
Anne-Marie Martin Ph.D.
Senior Vice President and Global Head of Precision Medicine, Novartis
Anne-Marie (Annie) Martin, Ph.D., joined Novartis Oncology in 2016 and is the Senior Vice President and Global Head of Precision Medicine.
In her role as Global Head of Precision Medicine, Annie leads the development, registration and approval of in vitro diagnostics alongside the development of all pipeline drugs in Global Drug Development. Furthermore, Annie is accountable for all correlative sciences and biomarker activities to support all Oncology drugs in the development phase. Since joining NVS, Annie has led the successful development, regulatory submission and approval of companion diagnostics for midostaurin – a Flt3 inhibitor for AML and ASM. In addition, she led the development of the ALK IHC companion diagnostic for ceritinib and she led the development of the first NGS companion diagnostic in support of dabrafenib and trametinib for BRAF mutant NSCLC. Since joining NVS, Annie has contributed to the advancement of several cancer medicines including alpelisib and ribociclib. Prior to Novartis, Annie was the Global Head of Precision Medicine and she was the Global Head of Molecular Medicine for R&D at GlaxoSmithKline where she contributed to the development of lapatinib, pazopinib, ofatumumab, eltrombopag, dabrafenib and mekinist. In addition, she was Vice President of Biomarker Research at Adaptimmune LLC in Philadelphia.
Annie received her PhD. In Microbiology and Immunology from Hahnemann University in Philadelphia and she completed her Postdoctoral training at the University of Pennsylvania, Pennsylvania. Prior to joining Industry, Annie held an adjunct Professor position in the Departments of Haematology and Oncology and Surgical Oncology at UPENN and she was Director of the Molecular Pathology Department at Pennsylvania Hospital. Annie is an author of several manuscripts and abstracts published in peer reviewed journals and presented at major conferences. Annie is a recipient of several government grants, academic and corporate awards.
Glenn A. Miller, Ph.D.
Partners Healthcare Innovation’s Market Sector Leader for Radiology, Anesthesiology, Neurology, Neurosurgery and Psychiatry
Dr. Miller is Partners Healthcare Innovation’s Market Sector Leader for Radiology, Anesthesiology, Neurology, Neurosurgery and Psychiatry. Before joining Partners, Dr. Miller was President of CDx Vision, a consultancy specializing in Precision Medicine and Companion Diagnostics. Dr. Miller has nearly 30 years of experience in the clinical laboratory industry and personalized medicine including serving as Executive Vice President and Chief Technology Officer of MolecularMD; Vice President and Head of Personalized Healthcare and Biomarker Strategy, Portfolio and Alliances for AstraZeneca Pharmaceuticals; and leading Genzyme Analytical Services as Vice President and General Manager. Dr. Miller also serves as Chair of the Scientific Advisory Board and is a member of the Board of Directors of Biomarker Strategies. He received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo. He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami School of Medicine.
Robert S. Miller, MD, FACP, FASCO
Vice President and Medical Director, CancerLinQ®
Robert S. Miller, MD, FACP, FASCO is Vice President and Medical Director, CancerLinQ®, a big data, health technology platform for oncology developed by the American Society of Clinical Oncology (ASCO). He provides medical oversight and clinical input for all aspects of CancerLinQ development and operations. He is also primary staff support for the CancerLinQ physician committees and product development team lead. Previously, he was ASCO Vice President for Quality and Guidelines, responsible for clinical practice guidelines, performance measurement, the Quality Oncology Practice Initiative, and quality informatics. From 2009 to 2014, he served as Oncology Medical Information Officer at the Kimmel Comprehensive Cancer Center at Johns Hopkins and specialized in the care of patients with breast cancer. His additional professional experience included the community practice of oncology in California, where he was president of the Sacramento Center for Hematology and Medical Oncology, and hospice medical director. He is board certified in internal medicine, medical oncology, and clinical informatics
Spyro Mousses, PhD
Executive Scientific Advisor, Medical Intelligence and Innovation Institute Children’s Hospital of Orange County, CEO Systems Oncology
Spyro Mousses PhD
Scientific Background: Dr. Mousses’ scientific expertise include cancer research, genome sciences, pharmaceutical sciences, and computational technologies. His career has focused on developing innovative approaches for translating large scale molecular and genomic information into novel therapeutic insights and precision medicine strategies. As an accomplished thought leader and innovator, he has published numerous patents and peer-reviewed papers on multiple scientific advances, including new platform technologies for high throughput functional genomics, breakthrough discoveries of new cancer targets, novel cancer drug treatments including innovative combination strategies, and pioneering computational approaches to resolve the molecular complexity of cancer. Since 2009, he has focused on developing an innovative AI platform capable of revolutionizing the field of cognitive computing. His pioneering research in this field led to the development of a new hypergraph framework that can integrate disparate Big-Data sources into unified knowledge networks, and his team is currently developing automated approaches based on human cognition to mine knowledge networks using machine learning. This approach has led to the discovery of truly novel insights into molecular mechanisms of cancer, and this approach is now being used by Systems Oncology for faster drug discovery, smarter drug development, and precision oncology.
Academic Background: Dr. Mousses received his BSc (1991) (Pharmacology and Toxicology), MSc (1993) and PhD (1998) (Molecular Pathogenesis and Genetics of Cancer), from the University of Toronto, Canada. He served as Staff Scientist at the National Human Genome Research Institute, National Institutes of Health (NIH) in Bethesda MD, where he led a program in cancer genome scanning and high throughput technology development (1998-2002). He joined the Translational Genomics Research Institute (TGen – Phoenix AZ) at the inception of the Institute as one of the founding scientists (2002), contributing to the building and directing the Cancer Drug Development Laboratory, the Pharmaceutical Genomics Division until 2010, and served as the Director of the Center for BioIntelligence and Vice President in the Office of Innovation until 2014. In his role as Head of Innovation at TGen, Dr. Mousses developed extensive experience in leading large multi-disciplinary private/public collaborations and architected partnerships with more than 20 major corporations in the pharmaceutical, biotech, life sciences, and IT industries. Academically, Dr. Mousses continues to sit on multiple Scientific Advisory Boards and serves as a scientific advisor to multiple international groups including BMS, Terry Fox Research Institute, Medical Intelligence and Innovation Institute at CHOC, International Society for Pediatric Innovation, and the Artificial Intelligence in Medicine (AIMed) organization.
Entrepreneurial Background: Dr. Mousses is also an innovation driven entrepreneur with a passion for advancing life-saving scientific innovations to the marketplace. He previously co-founder of Systems Medicine Inc (acquired by Cell Therapeutics Inc.), and MedTrust OnLine Inc. (acquired by Annai Systems Inc.). In 2014, Dr. Mousses left academia to start Systems Imagination Inc., an AI technology company developing computational solutions and offering data mining services to help leading pharmaceutical companies resolve systems complexity and thereby accelerate the recover knowledge from Big Data. Dr. Mousses later co-founded Systems Oncology (SO), a biopharmaceutical products company, focused on applying these computational approaches directly to cancer drug discovery and development. Systems Oncology and Systems Imagination have been partners since 2015 to combine forces to bring the exponential power of Big Data and AI to cancer drug discovery and development.
Melanie Nallicheri, MBA
Chief Business Officer and Head, Biopharma, Foundation Medicine
Melanie joined Foundation Medicine in 2016 as Chief Business Officer and head, Biopharma. She brings more than 25 years of experience in corporate strategy and business development.
Previously, Melanie was senior vice president, corporate strategy and business development, McKesson Distribution Solutions and McKesson Data & Analytics. She was responsible for identifying growth opportunities and working closely with the executive committee and operating team to drive business growth, financial performance and strategy execution. She was also senior vice president, corporate development at Geron Corporation and a partner and senior member of the global health practice at Booz & Company/Booz Allen Hamilton.
She has been on the board of the American Red Cross Bay Area Chapter, Bay Area Council and Healthcare Business Women’s Association.
Melanie earned her MBA with honors from Columbia Business School, and her MS in business and economics from WHU Otto Beisheim School of Corporate Management in Koblenz, Germany.
Vaibhav Narayan, PhD, MBA
Vice President of Research IT, Janssen Pharmaceuticals LLC
Vaibhav is currently Vice President of Research IT at Janssen Pharmaceuticals LLC. where he is responsible for programs that utilize data, analytics and digital health technologies to transform research innovation capabilities across Janssen R&D. Vaibhav also holds the position of Head, Integrated Solutions, Janssen Neuroscience. In this role, Vaibhav is leading efforts to develop technology enabled solutions for early detection, disease monitoring and relapse prediction in Alzheimer’s Disease, Major Depressive Disorders and Schizophrenia.
Vaibhav joined Johnson and Johnson from Eli Lilly and Co., where he headed the Discovery and Biomedical Informatics group responsible for enabling Eli Lilly’s translational, biomarker, and tailored therapeutics strategies. Prior to Eli Lilly, Vaibhav held multiple leadership roles in various small to mid-size biotech companies such as Celera Genomics, CuraGen Corporation and Vertex pharmaceuticals during which time he participated in multiple landmark ‘Big Biology’ projects, including sequencing, assembly and analysis of the human genome (the Human Genome Project).
Vaibhav obtained his PhD from Yale University jointly from the Departments of Chemistry, and Molecular Biophysics & Biochemistry in 1998, and an Executive MBA from Kellogg School of Management, Northwestern University in 2009.
Melissa J. Nirenberg, MD, PhD
Chief Medical Officer of The New York Stem Cell Foundation
Melissa J. Nirenberg, MD, PhD is the Chief Medical Officer (CMO) of The New York Stem Cell Foundation (NYSCF), and an Adjunct Professor of Neurology at the NYU School of Medicine. She joined NYSCF as its inaugural CMO in September 2017. Dr. Nirenberg pursued her undergraduate education at Yale University, graduating magna cum laude with Distinction in English. She received her MD and a PhD in Neuroscience from the Tri-Insitutional MD-PhD program at Weill Cornell, where her doctoral research included investigation of the neuroanatomy of the dopamine-containing neurons that are affected in Parkinson’s disease and related disorders. She subsequently completed residency training in Neurology at the University of California, San Francisco, followed by a fellowship in Movement Disorders at Columbia University. In 2005, Dr. Nirenberg joined the faculty of Weill Cornell Medicine as an Assistant Professor of Neurology and Associate Director of the Division of Movement Disorders. While she was at Weill Cornell, she was also appointed Associate Director of the Tri-Institutional MD-PhD program. In 2012, Dr. Nirenberg joined NYU Langone Health as an Associate Professor of Neurology in the Division of Movement Disorders, where she was also Associate Director of the NYU Neurology Residency program.
Nate Nussbaum MD
Medical Director, Flatiron Health
Nate Nussbaum is a practicing medical oncologist who serves as medical director at Flatiron Health, where he focuses on conducting outcomes research. He also specializes in assembling real-world research datasets and developing approaches to integrate technology into dataset creation.
Nate maintains a clinical practice at Bellevue Hospital’s Cancer Center and has an appointment as a clinical instructor at New York University School of Medicine. He is board-certified in internal medicine and medical oncology.
Nate received his MD from the Johns Hopkins University and trained in internal medicine at the Hospital of the University of Pennsylvania. He then completed his medical oncology fellowship at Duke University, where he was also a fellow at the Duke Clinical Research Institute. Nate has a Bachelor’s degree from Yale University. Before entering medicine, he worked as an associate consultant at Bain & Company.
Ana Oromendia, PhD.
Genomics Business Analytics Manager at Medidata Solutions
Ana Oromendia: Genomics Business Analytics Manager at Medidata Solutions, with over 10 years of experience in genomics and scientific software development. Her background includes the experimental and analysis design of large 'omic datasets, participating in large multidisciplinary scientific collaborations and the development of a genetic assay and accompanying software. At Medidata, Ana is part of the Data Science team creating analytical tools to improve the efficiency and rigor of clinical trials, including the development of the Rave Genomics solution. Ana received her PhD in molecular genetics from the Massachusetts Institute of Technology where she was part of the interdisciplinary Koch Institute for Integrative Cancer Research
Maria Palombini, MBA
Director, Emerging Communities & Initiatives Development, Global Business Strategy & Intelligence, IEEE Standards Association
Maria is the creator, leader and advocate for the Pharma Blockchain Initiative, which seeks to bring awareness and balanced learning to the pharmaceutical community and its key stakeholders on the viable applications of blockchain within the pharmaceutical framework. The goal of the initiative is advance adoption of blockchain in combination with emerging technologies (ie. AI, IoT, etc) where it will lead to enhanced patient safety and care, and optimize and innovate the drug development lifescyle.
In 2017, Maria joined IEEE-SA with a directive to build communities and advance initiatives to develop standards for enterprise adoption of emerging technologies. Her work includes building communities of technologists, industry executives, academic researchers and industry stakeholders to educate on the benefits and challenges of viable applications of emerging technologies, while building consensus on recommendations for frameworks on technical standards and recommended guidelines for protocol and policies to enhance the outcomes of technology implementation. Her primary areas of focus include the pharma, health, supply chain, energy, and agriculture sectors. In parallel to her work in blockchain standards, she is the project lead for IEEE-SA’s newest initiative, Digital Inclusion through Trust and Agency, a critical program focused on bringing the outstanding 50% of the world’s population online while working with technologists, advocacy groups and policy leaders on developing trusted frameworks that will protect the digital persona, the right to be forgotten, and restoring dignity to digital transactions for ALL members of the global community.
In 2015, Maria left Euromoney Plc, one of the world’s leading information and event producers. She founded DisruptiveRx™, an information company that would produce written and in-person educational programs and bring pragmatic attention on breakthrough innovations that would transform life sciences and healthcare enterprise operations.
Her career started at the prestigious IEEE (Institute for Electronic and ElectricalEngineers) and moved onto highly respected media companies including Penton Media, Advanstar Communications, IIR, Reed Business Information and Nielsen Business Media. She successfully led the global branding, marketing and public relat